Advertisement
ABBV or BMY or ZTS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Bristol-Myers Squibb (BMY) vs. Zoetis (ZTS) Stock Comparison
Key Takeaways
- ABBV shares have shown steady gains in recent weeks, supported by positive Phase 3 data for SKYRIZI in Crohn's disease, with YTD returns around 1% and a 3% dividend yield.
- BMY leads YTD performance at over 13%, driven by FDA approval for Sotyktu in psoriatic arthritis and Reblozyl growth exceeding $2.3 billion annualized, offering a higher 4%+ yield.
- ZTS reported Q4 revenue growth of 3% but faces U.S. companion animal headwinds from softer clinic visits, with shares down YTD by about 3%.
- BMY trades at the lowest forward P/E among the three, appealing for value amid growth portfolio momentum.
- All three maintain low betas under 0.5, providing defensive positioning in healthcare relative performance.
- Recent market activity highlights contrasts: human pharma stability in ABBV and BMY versus animal health cyclicality in ZTS.
Introduction
This stock comparison examines ABBV, BMY, and ZTS, three leaders in animal and human healthcare. ABBV and BMY focus on biopharmaceuticals for immunology and oncology, while ZTS dominates animal health. Investors seeking defensive sector exposure with dividends and growth potential, or traders eyeing relative performance amid market volatility, will find value in analyzing their recent momentum, catalysts, and valuations. This analysis draws on current market positioning to aid informed decisions in healthcare stock comparison.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV) is a research-based biopharmaceutical company specializing in immunology, oncology, neuroscience, and aesthetics, with key products like Skyrizi, Rinvoq, and Botox. In recent market activity, ABBV shares have exhibited resilience, posting modest YTD gains around 1% and monthly increases near 3-10% in volatile sessions. Positive topline Phase 3 AFFIRM study results for Skyrizi (risankizumab) in moderately to severely active Crohn's disease have bolstered sentiment, achieving superiority in clinical remission and endoscopic response versus placebo. This reinforces immunology portfolio strength amid Humira erosion offset by newer drugs. With a market cap over $400 billion, forward P/E around 16, and 3% dividend yield, ABBV appeals for stability, though valuation concerns persist post strong performance.
BMY Overview and Recent Performance
Bristol-Myers Squibb Company (BMY) develops biopharmaceuticals in oncology, immunology, and cardiovascular areas, featuring Eliquis, Opdivo, and growth assets like Reblozyl and Sotyktu. Recent weeks have seen robust momentum, with shares up 6-11% monthly and YTD over 13%, outperforming peers. FDA approval for Sotyktu in psoriatic arthritis expands its immunology footprint, while Reblozyl tops $2.3 billion annualized sales, aided by positive Phase 2 data in alpha-thalassemia anemia. Despite legacy declines, growth portfolio offsets pressures, supporting a $120+ billion market cap, forward P/E near 10, and 4%+ yield. Low beta underscores defensive appeal in relative performance.
ZTS Overview and Recent Performance
Zoetis Inc. (ZTS), the leading animal health firm, offers vaccines, medicines, and diagnostics for companion and livestock animals, including Simparica and Librela. Q4 results showed 3% revenue growth to $2.4 billion, beating estimates, with 4% organic operational rise, though U.S. companion animal softened due to fewer clinic visits from price-sensitive owners. Shares reflect caution, down ~3% YTD amid competitive pressures in dermatology and pain. International growth and livestock strength provide balance, with a ~$55 billion market cap, forward P/E ~17-23, and lower yield. Recent activity highlights cyclical exposure versus human pharma peers.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases over 25 top-performing AI trading bots curated from hundreds available, which collectively trade thousands of tickers across stocks, ETFs, and crypto. Selected by AI analysis for suitability in current volatility (low, medium, high), these bots feature impressive stats: annualized returns up to +215%, win rates to 95%, and profit factors over 25. Examples include biotechnology bots with 90%+ wins on leveraged ETFs and multi-ticker strategies in semiconductors or aerospace yielding 100%+ returns. Varying by style—scalping, swing, long-term—these adapt to market conditions. Explore Trending AI Robots to identify bots matching your strategy.
Head-to-Head Comparison
ABBV, BMY, and ZTS operate in healthcare but diverge in focus: human biopharma for the former two versus animal health for ZTS. Growth drivers contrast—ABBV's immunology (Skyrizi/Rinvoq) and aesthetics versus BMY's oncology/immunology (Opdivo/Reblozyl) and ZTS's parasiticide/diagnostics cyclicality. Recent momentum favors BMY (13%+ YTD) over ABBV (1%) and lagging ZTS (-3%). Risk factors include patent cliffs for all, but ZTS faces pet spending sensitivity. Sector exposure: human therapeutics more recession-resistant than livestock/companion. Valuation sensitivity shows BMY cheapest (forward P/E ~10), ABBV mid (~16), ZTS premium (~20). Market sentiment tilts to BMY for yield/value trade-off.
Tickeron AI Verdict
Tickeron’s AI currently favors BMY based on superior trend consistency, YTD outperformance, attractive valuation, high yield, and catalysts like Sotyktu approval and Reblozyl expansion. While ABBV offers immunology stability and ZTS international livestock growth, BMY's relative positioning suggests higher probability of near-term upside in current conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s), and ZTS’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- BMY’s FA Score: 2 green, 3 red.
- ZTS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while BMY’s TA Score has 6 bullish TA indicator(s), and ZTS’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- BMY’s TA Score: 6 bullish, 4 bearish.
- ZTS’s TA Score: 4 bullish, 6 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.70% price change this week, while BMY (@Pharmaceuticals: Major) price change was -0.22% , and ZTS (@Pharmaceuticals: Generic) price fluctuated +1.74% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.87%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +6.57%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.55%. For the same industry, the average monthly price growth was +3.94%, and the average quarterly price growth was -0.03%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
BMY is expected to report earnings on Apr 30, 2026.
ZTS is expected to report earnings on May 07, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.87% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Pharmaceuticals: Generic (+3.55% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| ABBV | BMY | ZTS | |
| Capitalization | 376B | 121B | 50.5B |
| EBITDA | 17.6B | 15.2B | 4.07B |
| Gain YTD | -6.294 | 12.705 | -4.226 |
| P/E Ratio | 89.62 | 17.19 | 19.93 |
| Revenue | 61.2B | 48.2B | 9.47B |
| Total Cash | 5.26B | N/A | 2.31B |
| Total Debt | 67.5B | 47.1B | 9.24B |
ABBV | BMY | ZTS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 8 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 5 Undervalued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 13 | 78 | 100 | |
SMR RATING 1..100 | 1 | 23 | 16 | |
PRICE GROWTH RATING 1..100 | 59 | 47 | 61 | |
P/E GROWTH RATING 1..100 | 40 | 66 | 85 | |
SEASONALITY SCORE 1..100 | 4 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (5) in the Pharmaceuticals Major industry is in the same range as ZTS (30) in the Pharmaceuticals Generic industry, and is somewhat better than the same rating for ABBV (38) in the Pharmaceuticals Major industry. This means that BMY's stock grew similarly to ZTS’s and somewhat faster than ABBV’s over the last 12 months.
ABBV's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (78) in the Pharmaceuticals Major industry, and is significantly better than the same rating for ZTS (100) in the Pharmaceuticals Generic industry. This means that ABBV's stock grew somewhat faster than BMY’s and significantly faster than ZTS’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as ZTS (16) in the Pharmaceuticals Generic industry, and is in the same range as BMY (23) in the Pharmaceuticals Major industry. This means that ABBV's stock grew similarly to ZTS’s and similarly to BMY’s over the last 12 months.
BMY's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as ABBV (59) in the Pharmaceuticals Major industry, and is in the same range as ZTS (61) in the Pharmaceuticals Generic industry. This means that BMY's stock grew similarly to ABBV’s and similarly to ZTS’s over the last 12 months.
ABBV's P/E Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as BMY (66) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that ABBV's stock grew similarly to BMY’s and somewhat faster than ZTS’s over the last 12 months.
| ABBV | BMY | ZTS | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 33% | 1 day ago 56% | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 68% | 1 day ago 45% | 1 day ago 62% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 51% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 60% | 1 day ago 63% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 47% | 1 day ago 54% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 51% | 1 day ago 56% | 1 day ago 63% |
| Advances ODDS (%) | 1 day ago 57% | 1 day ago 53% | 1 day ago 52% |
| Declines ODDS (%) | 4 days ago 47% | 4 days ago 53% | 15 days ago 58% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 48% | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 45% | 1 day ago 52% | 1 day ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TOPT | 29.98 | 0.30 | +1.01% |
| iShares Top 20 U.S. Stocks ETF | |||
| XLRE | 42.73 | 0.29 | +0.68% |
| State Street Real Estate Sel SectSPDRETF | |||
| IVVB | 32.83 | 0.09 | +0.27% |
| iShares Large Cap Deep Qt Ldrd ETF | |||
| XTL | 207.07 | 0.11 | +0.05% |
| State Street® SPDR® S&P® Telecom ETF | |||
| SIMS | 43.40 | N/A | N/A |
| Stt Strt®SPDR®S&PKenshoIntlgntStrctrETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.38% | ||
| BMY - ABBV | 58% Loosely correlated | +0.46% | ||
| PFE - ABBV | 57% Loosely correlated | -0.91% | ||
| BIIB - ABBV | 55% Loosely correlated | -1.55% | ||
| AMGN - ABBV | 53% Loosely correlated | +1.66% | ||
| NVS - ABBV | 52% Loosely correlated | +0.41% | ||
More | ||||
ZTS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.
| Ticker / NAME | Correlation To ZTS | 1D Price Change % | ||
|---|---|---|---|---|
| ZTS | 100% | +0.20% | ||
| ELAN - ZTS | 52% Loosely correlated | -0.59% | ||
| VTRS - ZTS | 44% Loosely correlated | +0.26% | ||
| PRGO - ZTS | 41% Loosely correlated | -2.12% | ||
| PAHC - ZTS | 39% Loosely correlated | +0.78% | ||
| HLN - ZTS | 39% Loosely correlated | +0.40% | ||
More | ||||